Literature DB >> 3007777

Naltrexone.

H D Kleber.   

Abstract

Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3007777     DOI： 10.1016/0740-5472(85)90036-4

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN： 0740-5472


  9 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

2.  Assessment of drug abuser treatment needs in Rhode Island.

Authors:  W E McAuliffe; P Breer; N W Ahmadifar; C Spino
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

Review 3.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

Review 4.  Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Authors:  Jeanette M Tetrault; David A Fiellin
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

Review 5.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

Review 6.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

7.  Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.

Authors:  Reza Afshari; Majid Khadem-Rezaiyan; Hoda Khatibi Moghadam; Mahdi Talebi
Journal:  Toxicol Res       Date:  2019-11-21

8.  Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal.

Authors:  D B Vaupel; A S Kimes; E D London
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

9.  The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis.

Authors:  Moein Zangiabadian; Saeid Golmohammadi; Seyed Aria Nejadghaderi; Mohammad Mahdi Zahmatkesh; Mohammad Javad Nasiri; Majid Sadeghian
Journal:  Front Psychiatry       Date:  2022-09-26       Impact factor: 5.435
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.